PT - JOURNAL ARTICLE AU - Yihao Liu AU - Qin Zeng AU - Caiguanxi Deng AU - Mengyuan Li AU - Liubing Li AU - Dayue Liu AU - Jie Mei AU - Ruohui Mo AU - Qian Zhou AU - Min Liu AU - Sui Peng AU - Ji Wang AU - Hui Zhang AU - Haipeng Xiao TI - Robust induction of B cell and T cell responses by a third dose of inactivated SARS-CoV-2 vaccine AID - 10.1101/2021.09.12.21263373 DP - 2021 Jan 01 TA - medRxiv PG - 2021.09.12.21263373 4099 - http://medrxiv.org/content/early/2021/09/15/2021.09.12.21263373.short 4100 - http://medrxiv.org/content/early/2021/09/15/2021.09.12.21263373.full AB - SARS-CoV-2 inactivated vaccines have shown remarkable efficacy in clinical trials, especially in reducing severe illness and casualty. However, the waning of humoral immunity over time has raised concern over the durability of immune memory following vaccination. Thus, we conducted a non-randomized trial among the healthcare professionals (HCWs) to investigate the long-term sustainability of SARS-CoV-2-specific B cells and T cells stimulated by inactivated vaccine and the potential need for a third booster dose for the HCWs. Although neutralizing antibodies elicited by the standard two-dose vaccination schedule dropped from a peak of 31.2 AU/ml to 9.2 AU/ml 5 months after the second vaccination, spike-specific memory B and T cells were still detectable, forming the basis for a quick recall response. As expected, the faded humoral immune response was vigorously elevated to 66.8 AU/ml by 7.2 folds 1 week after the third dose along with abundant spike-specific circulating follicular helper T cells in parallel. Meanwhile, spike-specific CD4+ and CD8+ T cells were also robustly elevated by 5.9 and 2.7 folds respectively. Robust expansion of memory pools by the third dose potentiated greater durability of protective immune responses. Another key finding in this trial was that HCWs with low serological response to 2 doses were not truly “no responders” but fully equipped with immune memory that could be quickly recalled by a third dose even 5 months after the second vaccination. Collectively, these data provide insights into the generation of long-term immunological memory by the inactivated vaccine, which has implications for future booster strategies that the frontline HCWs, individuals with low serological response to 2 dose of vaccine and immune compromised patients could benefit from a third dose of inactivated vaccine.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialChiCTR2100042222 and ChiCTR2100048665Funding StatementThe work is supported by The Talent Program of the First Affiliated Hospital, Sun Yat-sen University (Y70311) and The Hundred Talent Program of Sun Yat-sen Univetsity (Y61229).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Volunteer recruitment and blood sample collection were approved by Institutional Review Board of the First Affiliated Hospital of Sun Yat-sen University. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data were included in the current form of manuscript.